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The immunosuppressant FK506, which is more
potent and less toxic when compared with cyclo-
sporine,1 has become widely used in clinical organ
transplantation.2 da Gama et al3 reported satisfactory
results of arterial allografting in human subjects who
had received immunosuppressive treatment for other
organ transplantation. These reports suggest that 
an immunosuppressive treatment is essential in
obtaining acceptable results in vascular allografting.
Although many experimental studies on vascular allo-
graft rejection with an emphasis on cellular immunol-
ogy, cytokines, adhesion molecules, and humoral
immunology were performed,4,5 there is little com-
prehensive literature addressing denudation and
regeneration of endothelial cells (ECs), which are
essential in graft patency. Williams et al6 and Perloff
et al7 demonstrated in transplantation studies of rat
allografts with the sex chromatin body that the EC
repopulation was derived from the recipient artery.
Nevertheless, the influence of immunosuppressive
agents on EC regeneration still remained unclear,
and further investigation of the process of EC
denudation and regeneration is important for under-
standing the rejection process and helping to consid-
er an immunosuppressive strategy for vascular allo-
grafting.
This study investigated: (1) the process of EC
denudation and repopulation in arterial allografts;
(2) the efficacy of FK506 on the process; and (3) the
possibility of reducing or discontinuing FK506.
MATERIALS AND METHODS
Male ACI rats (RT1a) weighing 200 to 270 g
(241 ± 17 g) were used as donors, and male ACI
and male Lewis (LEW) rats (RT1l) weighing 300 to
390 g (336 ± 31 g) were used as the isogeneic and
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allogeneic recipients, respectively. These two inbred
strains, which had different major histocompatibility
complex, were chosen because of their immunolog-
ical incompatibility, which is known from other
organ transplant models.8,9 These animals were
obtained from commercial sources (Lewis rats:
Charles River, Japan; ACI rats: Hoshino Experiment
Animals, Japan), and their care and use complied
with the “Principles of Laboratory Animal Care and
the Guide for the Care and Use of Laboratory
Animals” (National Institutes of Health Publication
#80-23, revised 1985).
Arterial transplantation study. Seventy-six
animals were anesthetized with intraperitoneal injec-
tions of sodium pentobarbital (30 to 40 mg/kg).
Under an operating microscope of · 16 magnifica-
tion, a 5-to-6-mm-long segment of the common
carotid artery was removed from the donor rat and
interposed between the divided ends of the common
carotid artery in the recipient rat by an end-to-end
anastomosis with continuous 11-0 nylon sutures.
The ischemic time of the donor arteries ranged from
55 to 120 minutes (77.9 ± 18.1 minutes). 
The experiment was performed on four groups
(Table I): group I was the isogeneic control (n =
29); group II consisted of allografts without
immunosuppression (n = 26); groups III and IV
included those allografts that received low-dose
FK506 every day from day 3 after transplantation
until they were killed (group III, n = 15) or until the
cessation of the use of FK506 on day 28 (group IV,
n = 6). FK506 (tacrolimus; Fujisawa Pharmaceutical,
Osaka, Japan) was suspended in normal saline and
given intramuscularly in daily doses of 0.2 mg/kg.
Neither anticoagulants nor antiplatelet agents were
administered throughout the experiment.
Graft removal. The grafts were retrieved at 1
hour, 1 day, 3 days, 1 week, 2, 3, 4, 10, and 15
weeks after transplantation in groups I and II, and at
1, 2, 3, 4, and 10 weeks in group III. In group IV,
the administration of FK506 was stopped 4 weeks
after transplantation, and the grafts were then
retrieved 2, 3, and 11 weeks after the cessation of
the use of FK506 (Table I). All grafts were processed
for histology, immunohistochemistry, and scanning
electron microscopy (SEM).
Scanning electron microscopy and morphom-
etry. For quantitative evaluation of the extent of
de-endothelialization and re-endothelialization, the
proximal halves of the retrieved grafts were exam-
ined by means of SEM (Hitachi, Tokyo, Japan).
Each specimen obtained was fixed overnight with 1%
glutaraldehyde in 0.2 mol/L phosphate buffered
saline (PBS). After rinsing in PBS (pH, 7.4), the
specimens were postfixed in 1% osmium tetroxide,
dehydrated, dried in the critical point dryer, and
sputter-coated with platinum. The luminal surface of
the specimens (from anastomosis to the midportion
of the graft) were then observed at a magnification
of · 300, and serial photographs were taken with an
image processor (EP-3000, Hitachi). A computer-
aided morphometric analysis system (Macintosh,
Apple Computer, Cupertino, Calif) with the public
domain program “Image” (NIH Research Service
Branch, NIH, Bethesda, Md) was used to measure
the regions covered by ECs, and the percentage of
the EC coverage area (%-EC) was determined by
means of the following equation: 
%-EC area = area covered with ECs ÷ (total lumi-
nal surface area – area involved artifact) · 100.
Quantitative evaluation of histology. The
midportion of the graft segment was fixed with 10%
natural buffered formalin. After fixation, the speci-
mens were embedded in paraffin, cross sectioned,
and stained with the hematoxylin eosin and Elastica
van Gieson methods. To assess the histological
changes of rejection, medial and adventitial cell infil-
tration, medial degeneration, and intimal thickening
were quantified in the following manner: For evalu-
ation of the cellularity in adventitia or media, nuclei
Table I. Summary of experimental groups
Strain Implantation time
Group combination FK506 regimen (days after transplantation)
I ACI-ACI – 0‡, 1, 3, 7, 14, 21, 28, 70, 105
II ACI-LEW – 0§, 1, 3, 7, 14, 21, 28, 70, 105
III ACI-LEW 0.2 mg/kg/day from day 3 until killed 7, 14*, 21, 28*, 70
IV ACI-LEW 0.2 mg/kg/day from day 3 for 4 weeks; no treatment thereafter 42†, 49*, 105*
The number of samples available for evaluation at each implantation was three, with some exceptions (*n = 2; †n = 1).
‡Prereperfusion (immediately after anastomosis, n = 3) and 1 hour after transplantation (n = 2).
§One hour after transplantation (n = 2).
LEW, Lewis rats. 
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within each layer were counted using a 25- m m-
square grid in the eyepiece at a magnification of
· 400. A minimum of four randomly selected fields
were counted for each section, and the cellularity
was expressed as the average of the number of nuclei
per 0.01 mm2. To estimate the intimal thickening
and medial degeneration, each section stained with
Elastica van Gieson was photographed, and the
cross-section area of the intima and media was then
measured with the computer system. The degree of
intimal thickening and medial degeneration was
expressed with a ratio of intimal to medial cross-sec-
tion area measured.
Immunohistochemistry. To confirm that the
cells covering the luminal surface of the grafts were
ECs, immunochemical stains for rat EC specific
antigen I (RECA-I)10 were performed, with the
labeled avidin-biotin technique. Frozen cross sec-
tions were obtained from the midportion of the
grafts, air-dried, and fixed in acetone. After block-
ing with bovine serum for 30 minutes, mouse anti-
RECA-I (Serotec, Oxford, United Kingdom), as
the primary antibody, was applied for 30 minutes
with 1:20 dilution of tris buffered saline. After
washing with tris buffered saline three times for 5
minutes each, the sections were incubated with a
biotinylated donkey anti-mouse IgG (DAKO,
Carpinteria, Calif) for 30 minutes, were washed,
and received an application of alkaline phosphatase-
labeled streptavidin (DAKO), followed by sub-
strate-chromogen (New Fuchsin, DAKO).
Statistical analysis. All values were expressed as
mean ± SD. Differences between groups I, II, and
III at each point were tested by the Kruskal-Wallis
analysis of variance of ranks. The Kruskal-Wallis sta-
tistic H was calculated with a personal computer
with StatView 4.5 (Abacus Concepts, Berkeley,
Calif), and the P value was obtained from the table
of probabilities for the Kruskal-Wallis analysis.11
Differences were considered statistically significant
when P was less than .05.
RESULTS
Seventy-six grafts were successfully transplanted,
but one in group IV was ruled out because of a
growing wound hematoma recognized 7 days after
transplantation. The remaining 75 grafts were patent
at the time of harvesting, but two in group III were
also excluded from the data because of damage that
occurred during preparation of the specimens. Table
I summarizes the number of the grafts available for
evaluation in each group.
Group I. The isografts at prereperfusion (imme-
diately after anastomosis) demonstrated extensive EC
loss (%-EC, 31% ± 10.5%), especially around the anas-
tomotic site. After transplantation, ECs remained at
the midportion of the grafts multifocally on the first
day, and multifoci of endothelial regeneration were
recognized as early as day 3. There were no remark-
able changes in the graft wall, except for slight inflam-
matory leukocytosis in adventitia at day 7, which 
was caused by the implantation procedure; re-
endothelialization in the entire graft was almost com-
pleted within 2 weeks after transplantation (Table II).
Group II. In the allografts, the denudation and
subsequent re-endothelialization were observed at
the same rate of progress as that in the isografts until
day 7 (Fig 1A and B). However, adhesion of numer-
ous leukocytes to the neointima occurred on day 14
(Fig 1C), and the graft denuded again (Fig 1D). The
%-EC of the allografts at 14 days was significantly
lower when compared with those of other groups (P
< .05, Table II). Nevertheless, re-endothelialization
of the allografts resumed slowly after 28 days, and
complete EC coverage of the luminal surface with-
out leukocyte adhesion was re-established 105 days
after transplantation (Fig 1E).
In the initial histological findings of rejection,
leukocyte adhesion on the intima accompanied by cell
infiltration in the adventitia was recognized approxi-
mately on day 14. The adventitial cell infiltration
reached a peak value on day 21; subsequently, degen-
eration of the medial smooth muscle cells appeared,
Table II. Results of endothelial cell coverage measurement
Area of endothelial cell coverage (%)
Group Day 1 Day 3 Day 7 Day 14 Day 21 Day 28 Day 70 Day 105
I 24.1 ± 16.9 77.6 ± 7.7 93.1 ± 4.2 93.5 ± 1.3 93.7 ± 7.8 91.8 ± 1.7 93.7 ± 3.0 99.4 ± 0.4
II 33.0 ± 6.1 69.8 ± 3.0 91.0 ± 5.2 67.3 ± 2.3 44.5 ± 19.8 81.7 ± 10.0 92.3 ± 4.3 92.2 ± 1.5
III – – 60.5 ± 24.4 87.0 ± 9.8 90.1 ± 5.8 93.2 ± 1.1 89.6 ± 6.0 –
P value – – .132 .025 .050 .200 > .664 –
Values are presented as mean ± SD.
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and karyopyknosis followed by karyolysis was com-
pleted by day 70 after transplantation. Intimal thick-
ening appeared 21 days after the drastic luminal dra-
matic changes demonstrated in SEM findings, reached
its maximum on day 70, and decreased slowly there-
after (Table III). The allografts lost most of their cel-
lular elements in both media and adventitia, resulting
in fibrosis; however, ECs remained on the luminal sur-
face of the thickened intima.
Although the inherent cell components of the
allografts almost disappeared at 105 days, a signifi-
cant number of inflammatory cells still remained in
the adventitia.
In groups III and IV, no adverse effects of
FK506, such as infection, loss of body weight, or
diarrhea, were observed.
Group III. The grafts demonstrated similar his-
tomorphological findings to those of the isografts in
Fig 1. Scanning electron microscopy aspects in the mid-
portion of untreated allografts. A, Residual endothelial
cells (arrows) found in midgraft as an islet-like aspect
without platelet adhesion at day 1 after transplantation.
B, Regenerated endothelial cells at day 7 in midgraft. 
C, Allograft at day 14. Note the massive leukocyte 
adhesion to neointima. D, Endothelial cell loss and inti-
mal destruction at day 21. Leukocytes still adhere to
remaining endothelial cells. Many platelets and fibrin
adhered to the exposed subendothelial connective tissue. 
E, Allografts at day 105. Re-endothelialization developed
again. (A, Original magnification, · 400; B, D, and E,
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group I. The histologic examination showed signifi-
cant suppression of the rejective response, and the
integrity of the cellular components in the arterial
wall was preserved (Fig 2A). Although a slight
leukocyte adhesion was recognized, a high percent-
age of the endothelial coverage area was maintained
after 14 days (Fig 3A).
Group IV. Massive leukocyte adhesion and 
EC loss were observed after the administration of
FK506 ended. In this group, desolation of the lumi-
nal surface was the most severe among all the exper-
imental groups. An extensive leukocyte adhesion to
the intima, EC loss, and remarkable adventitial cel-
lular infiltration were observed 2 weeks after the
administration of FK506 ended (Figs 2B and 3B).
Thereafter, the rejection progressed in a manner
similar to that of group II. The values of %-EC areas
at 14, 21, and 77 days after ceasing the administra-
tion of FK506 were 67.3%, 26.1% ± 14.9%, and
82.0% ± 8.5%, respectively. The adventitial nuclear
density, medial nuclear density, and intima/medial
area ratio were 47.1, 21.2, and 8.8 at day 14, 52.6
± 11.3, 51.5 ± 11.7, and 7.9 ± 5.8 at day 21, and
33.0 ± 8.7, 1.9 ± 1.1, and 118.6 ± 51.6 at day 77,
respectively. 
In immunohistochemistry with RECA-1, the
cells covering the luminal surface of the grafts were
stained red in all groups, demonstrating them to be
ECs (Fig 4).
DISCUSSION
Cryopreservation reduces the alloantigenicity.12
However, several experimental studies have con-
firmed that cryopreserved allografts still showed a
significant level of antigenicity,13,14 and results of
the use of venous allografts in patients with chronic
arterial occlusive disease have been disappointing,
despite the use of the recent cryopreservation tech-
nique.15-17 On the other hand, many experimental
studies proved the efficacy of cyclosporine in both
Fig 2. Light microscopic findings demonstrating effects of FK506 (A) and reactions after
cessation of the use of FK506 (B). A, Seventy-day allograft treated with FK506, showing
no evidence of rejection. B, Allograft at 14 days after cessation of the use of FK506,
demonstrating typical rejection with dense cell infiltration in adventitia and medial degen-
eration. (Original magnification, · 300.)
A B
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venous and arterial allograft implantation.18,19 This
study revealed the process of EC denudation and
regeneration of arterial allografts in the presence and
absence of immunosuppression and after cessation
of immunosuppressive treatment.
Our results concerning morphological changes of
the intimal surface of allografts without immunosup-
pression revealed two steps in the denudation and
regeneration process; the first process of denudation
and re-endothelialization occurred within 7 days
after transplantation, whereas the secondary process
occurred 14 to 21 days after transplantation. The first
denudation was thought to be caused by an ischemic
and mechanical injury accompanied by transplanta-
tion surgery, as observed in our isografts and in the
report of Macchiarelli et al.20 The secondary denuda-
tion was thought to be caused by massive leukocyte
adhesion as an immunologic reaction.
Although the direct origin of the regenerated
cells, donor or recipient, was not identified by means
of our methods, these sequential observations of the
entire graft suggested that the first re-endothelializa-
Fig 3. Scanning electron microscopy aspects demonstrating effects of FK506 (A) and reac-
tions after cessation of the use of FK506 (B). A, Seventy-day allograft treated with FK506,
showing well-healed endothelium. (Original magnification, · 1000.) B, Allograft at 14 days
after cessation of the use of FK506. Note the massive endothelial cell loss with leukocyte adhe-
sion. (Original magnification, · 600.)
A
B
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tion was donor in origin, because re-endothelializa-
tion developed from cells remaining in the center of
the graft toward the anastomotic site. These regen-
erated ECs subsequently became a target of leuko-
cyte attack. On the other hand, secondary re-
endothelialization was most likely recipient in origin,
because the endothelium was stable without leuko-
cyte adhesion. These findings were compatible with
the results of Williams’6 sex chromatin body analy-
sis, and Gohra et al21 also showed similar morpho-
logical results in a chronic rejection model.
The denudation and regeneration process of allo-
grafts in rats given FK506 was almost the same as
that of the isografts, revealing only slight leukocyte
adhesion and no secondary denudation. However, a
massive leukocyte adhesion appeared 2 weeks after
cessation of the use of FK506, and consequential
rapid progression of rejection was observed. These
Table III. Morphometric analysis of histology
Group Day 7 Day 14 Day 21 Day 28 Day 70 Day 105
Adventitial nuclear density (number of nuclei/0.01 mm2)
I 19.9 ± 3.0 16.2 ± 3.5 11.4 ± 3.1 9.6 ± 2.4 10.5 ± 1.9 7.3 ± 1.5
II 19.8 ± 6.8 49.3 ± 7.1 81.4 ± 15.1 56.1 ± 5.9 30.4 ± 7.4 17.2 ± 7.7
III 11.1 ± 4.4 16.0 ± 5.9 23.1 ± 1.7 11.5 ± 1.4 9.2 ± 0.2 –
P .050 .075 .004 .061 .050 –
Medial nuclear density (number of nuclei/0.01 mm2)
I 35.9 ± 2.0 25.5 ± 2.8 29.0 ± 1.5 25.9 ± 5.5 26.6 ± 11.3 27.1 ± 1.7
II 22.9 ± 3.4 25.8 ± 3.8 35.0 ± 14.8 11.2 ± 2.7 2.5 ± 2.6 0.9 ± 0.5
III 32.8 ± 9.2 38.3 ± 7.4 34.1 ± 3.6 22.2 ± 2.8 33.9 ± 4.8 –
P .100 .164 .361 .025 .050 –
Intima/medial area ratio (%)
I 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0
II 0 ± 0 0 ± 0 2.1 ± 1.8 4.5 ± 6.6 96.3 ± 112.9 61.2 ± 28.1
III 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 –
P – – .132 < .011 < .004 –
Values are presented as mean ± SD.
Fig 4. Immunohistochemistry of 105-day untreated allograft with rat endothelial cell specif-
ic antigen 1. The luminal surface monolayer of cells is positively stained. Vasa vasorum are also
stained. (Original magnification, · 400.)
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results suggest that donor-derived ECs regenerated
on the allograft after the first denudation, and those
cells could still survive on the allograft as long as the
immunosuppressant remained effective. In short, it
was suggested that most of the ECs on the allograft
may be of donor origin in their complete immuno-
suppressed condition. 
Endothelial denudation and regeneration influ-
enced the process of intimal hyperplasia. Randone et
al22 demonstrated that cytokines such as interleukin-1
might play a principal role in the genesis of intimal
hyperplasia in an allograft. Intimal hyperplasia, which
did not appear after the first denudation, occurred
severely after secondary denudation with massive
leukocyte adhesion. Therefore, immunosuppressive
treatment should be effective in preventing allograft
failure caused by intimal hyperplasia and endothelial
injury caused by massive leukocyte adhesion.
Many experimental studies that have used
immunosuppressants such as cyclosporine and
rapamycin have indicated that sufficient doses of
these agents suppressed the acute immunologic
reaction; however, a high dose of immunosuppres-
sants was necessary to prevent chronic rejection
involving intimal hyperplasia.23,24 Regarding the
dose of immunosuppressant, the minimal effective
dose of FK506 that provided significant prolonga-
tion of graft survival was thought to range between
0.04 and 0.1 mg/kg for cardiac allotransplantation
in the same animal model, whereas a daily dosage of
1.0 mg/kg was necessary to achieve long-term sur-
vival.8,9 In our preliminary study, doses of 1.0
mg/kg resulted in adverse effects such as diarrhea
and weight loss, whereas doses of 0.05 mg/kg 
provided effective immunosuppression, with occa-
sional low-grade leukocyte infiltration at adventitia.
Hence, the amount of FK506 used in the present
study was fixed at 0.2 mg/kg/day.
Although the allogenic heart in the same animal
model (ACI to LEW) was completely rejected by
day 6 after transplantation,8,9 our study showed that
rejection of arterial allograft started 2 weeks after
transplantation. The EC is thought to be the major
target of immunological response in primary rejec-
tion.25 Pardi and Bender26 reported that ECs were
killed by allogeneic cytotoxic T cell in vitro.
Lupinetti et al27 suggested that loss of ECs immedi-
ately after transplantation may contribute to the
delay in immunological responses against allografts.
To minimize the adverse effects of FK506, we also
delayed the administration of FK506 on the basis of
results of the pilot study, which revealed a delayed
onset of rejection in animals without FK506. Our
present study showed that FK506 suppressed
immunologic reaction without intimal hyperplasia,
even with administration starting on day 3 after
transplantation. This delayed administration of the
immunosuppressant also reduced adverse effects,
such as infection. 
Our results indicate that a relatively low dose 
of FK506 was sufficient to suppress the immune
response, even intimal hyperplasia, without major
adverse effects, whereas long-term administration of
FK506 was essential for preventing the immunologi-
cal reaction. However, it is not feasible to continue a
full dose of the immunosuppressant in all patients
who undergo a vascular allograft transplantation.
Callow28 contended that indication of vascular allo-
transplantation with immunosuppressant for patients
with limb ischemia should be limited to limb salvage,
because of its cost and the threat of adverse effects.
Nevertheless, the problem of unsatisfactory synthetic
grafts and the development of immunosuppressive
treatment have contributed to the recently renewed
interest in the allograft. Transplantation immunology
is rapidly progressing, and new immunological ther-
apies that may induce donor-specific immunotoler-
ance have been reported recently29,30; the donor-
antigen specific immunotherapy might develop arte-
rial allograft into an ideal conduit for small-caliber
arterial reconstruction.
In conclusion, ECs of allografts without immuno-
suppression revealed two steps of the denudation 
and regeneration process. FK506 proved to be valid
in rat arterial allografting, and ECs in the first re-
endothelialization, which was of donor origin, were
found to be able to survive on the allograft as long as
FK506 was effective; however, the cessation of the use
of FK506 resulted in severe destruction of intima.
Hence, to prevent allograft failure caused by the
immunological reaction, long-term administration of
FK506 is essential.
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